2012-10-10 21:37:36 - New Pharmaceuticals market report from Global Markets Direct: "Orion Oyj - Product Pipeline Review - 2012"

Global Market Direct's pharmaceuticals report, "Orion Oyj - Product Pipeline Review - 2012" provides data on the Orion Oyj's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Orion Oyj's corporate website, SEC filings, investor presentations and featured press releases, both from Orion Oyj and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Orion Oyj - Brief Orion Oyj overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Orion Oyj human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Orion Oyj with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Orion Oyj's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468575_orion_oyj_product_pipeline_review_201 ..


Reasons to buy

* Evaluate Orion Oyj's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Orion Oyj in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Orion Oyj's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Orion Oyj.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Orion Oyj and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Orion Oyj Snapshot
Orion Oyj Overview
Key Information
Key Facts
Orion Oyj - Research and Development Overview
Key Therapeutic Areas
Orion Oyj - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Orion Oyj - Pipeline Products Glance
Orion Oyj - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Orion Oyj Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Orion Oyj - Drug Profiles
Budesonide + Formoterol
Product Description
Mechanism of Action
R&D Progress
dexmedetomidine
Product Description
Mechanism of Action
R&D Progress
Fluticasone-Salmeterol Formulation
Product Description
Mechanism of Action
R&D Progress
levodopa
Product Description
Mechanism of Action
R&D Progress
ODM-201
Product Description
Mechanism of Action
R&D Progress
ORM-12741
Product Description
Mechanism of Action
R&D Progress
Stalevo
Product Description
Mechanism of Action
R&D Progress
Orion Oyj - Pipeline Products by Route of Administration
Orion Oyj - Pipeline Products By Mechanism of Action
Orion Oyj - Recent Pipeline Updates
Orion Oyj - Dormant Projects
Orion Oyj - Company Statement
Orion Oyj - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Orion Oyj, Recent Developments
Orion Oyj- Press Release
Jun 28, 2012: Selvita And Orion Pharma Achieve Research Milestone In Alzheimer's Disease Program
Apr 26, 2012: Orion Sues Mylan In US To Enforce US Patents Covering Stalevo
May 06, 2009: Orion reacquires rights for i.v. levosimendan (Simdax)
Mar 10, 2009: Orion Corporation withdraws its application for an extension of indication for Stalevo (levodopa/carbidopa/entacapone)
Financial Deals Landscape
Orion Oyj, Deals Summary
Orion Oyj, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Orion Acquires Rights To Simdax Drug From Abbott
Partnerships
Orion Diagnostica Enters Into Licensing Agreement With Immunodiagnostic Systems Holdings
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler
Eisai Enters Into Co-Marketing Agreement With Orion For Fareston And Eldepryl
Endo Pharma Enters Into Research Collaboration With Orion
Selvita Enters Into Co-Development Agreement With Orion
Orion Enters Into Distribution Agreement With Edmond Pharma For Erdotin
DelSiTech Enters Into Co-Development Agreement With Orion
Jubilant Biosys And Jubilant Chemsys Form Drug Discovery Partnership With Orion
ChemDiv Enters Into Co-Development Agreement With Orion Pharma
Medeia Therapeutics Enters Into Research Agreement With Orion
Aurigene Discovery Enters Into Drug Discovery Collaboration With Orion
Licensing Agreements
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler
Orion Enters Into Agreement With Recordati
Orion Enters Into Agreement With Indevus Pharma
Orion Enters Into Agreement With Oasmia Pharma
Orion Enters Into Agreement With Sanochemia Pharmazeutika

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468575&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.